Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Human recombinant interleukin-6 enhances antibody-dependent cellular cytotoxicity of human tumor cells mediated by human peripheral blood mononuclear cells

  • 42 Accesses

  • 20 Citations

Summary

The effects of human recombinant interleukin-6 (hrIL-6) on antibody-dependent cellular cytotoxicity (ADCC) activity mediated by human peripheral blood mononuclear cells (PMNC) were investigated. Human PMNC were preincubated for 24 h with various concentrations of hrIL-6 and were used as effector cells in a 4-h51Cr-release assay. The ability of hrIL-6 to augment ADCC was measured using anti-colorectal carcinoma mAbs D612, 17.1A and 31.1 (each directed against a distinct tumor antigen) and using three human colorectal carcinoma cell lines, LS-174T, WiDr and HT-29, as targets. A significant increase in ADCC activity was observed after PMNC were preincubated in 100–400 U/ml but not in lower concentrations of hrIL-6. Variations in activities of PMNC among donors were observed. Non-specific mAb showed no effect in augmenting ADCC activity. hrIL-6 treatment did not augment non-specific (non-mAb-mediated) cytotoxicity. The enhancement of ADCC activity was blocked by the addition of an antibody against hrIL-6 but not by an antibody to the IL-2 receptor (capable of blocking the induction of lymphokine-activated killer cell cytotoxicity by IL-2), suggesting that hrIL-6 augmentation of ADCC activity may not be mediated through IL-2. These results demonstrate that hrIL-6 augments ADCC activity of human PMNC using mAbs to human tumor antigens and human tumor cells as targets, suggesting a potential role for IL-6 in combination with anti-cancer antibodies for cancer immunotherapy.

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Bauman H, Prowse KR, Marinkovic S, Won KA, Jahreis GP (1989) Stimulation of hepatic acute phase response by cytokines and glucorticoids. Ann NY Acad. Sci 557: 280

  2. 2.

    Boyum A (1968) A one stage procedure for isolation of granulocytes and lymphocytes from human blood. Scand J Clin Lab Invest 21: 77

  3. 3.

    Burd PR, Freeman CJ, Wilson SD, Berman M, Dekruyff R, Billings PR, Dorf ME (1987) Cloning and characterization of a novel T cell activation gene. J Immunol 141: 1563

  4. 4.

    Chen L, Mory Y, Zlberstein A, Revel M (1988) Growth inhibition of human breast carcinoma and leukemia/lymphoma cell lines by recombinant interferon-β2. Proc Natl Acad Sci USA 85: 8037

  5. 5.

    Eisenthal A, Rosenberg SA (1989) The effect of various cytokines on the in vitro induction of antibody-dependent cellular cytotoxicity in murine cells. Enhancement of IL-2-induced antibody-dependent cellular cytotoxicity activity by IL-1 and tumor necrosis factor-α. J Immunol 142: 2307

  6. 6.

    Elias JA, Trinchieri G, Simon P, Kern J (1989) Interleukin-6 as a fibroblast-derived stimulator. Ann NY Acad Sci 557: 555

  7. 7.

    Erbe DR, Collin JE, Shen L, Graziano RF, Fanger MW (1990) The effect of cytokines in the expression and function of Fc receptors for IgG on human myeloid cells. Mol Immunol 27: 57

  8. 7a.

    Fersten PD, Primus FJ, Schlom J (1991) Characterization of the colorectal carcinoma-associated antigen defined by monoclonal antibody D612. Cancer Res 51: 926

  9. 8.

    Gallagher G, Stimson WH, Findlay J, Al-Azzaw F (1990) Interleukin-6 enhances the induction of human lymphokine-activated killer cells. Cancer Immunol Immunother 31: 49

  10. 9.

    Ganapath MK, May LT, Schultz D, Brabenec A, Weinstein J, Sehgal PB, Kushner I (1988) Role of interleukin-6 in regulating synthesis of c-reactive protein and serum amyloid A in human hepatoma cell lines. Biochem Biophys Res Commun 157: 271

  11. 10.

    Garman RD, Jacob KA, Clark SC, Raulet DH (1987) B-cell stimulating factor 2 (β2 interferon) functions as a second signal for interleukin-2 production by mature murine T cells. Proc Natl Acad Sci USA 84: 7629

  12. 11.

    Gauldie J, Richards C, Northemann W, Frey G, Baumann H (1989) IFNβ2/BSF2/IL-6 is the monocyte-derived HSF that regulates receptors-specific acute phase gene regulation in hepatocytes. Ann NY Acad Sci 557: 46

  13. 12.

    Henkart P, Yue CC (1988) The role of cytoplasmic granules in lymphocyte cytotoxicity. Prog Allergy 40: 82

  14. 13.

    Herberman RB, Hiserodt J, Vujanovic N, Balch C, Lozova E, Bolhuis R, Golub S, Lanier LL, Phillips JH, Riccardi C, Ritz J, Santoni A, Schmidt RE, Uchida A (1987) Lymphokine activated killer cell activity. Immunol Today 8: 178

  15. 14.

    Herlyn D, Herlyn M, Steplewski Z, Koprowski H (1979) Monoclonal antibodies in cell-mediated cytotoxicity against human melanoma and colorectal carcinoma. Eur J Immunol 9: 657

  16. 15.

    Herlyn M, Steplewski Z, Herlyn D, Koprowski H (1986) C) 17-1A and related monoclonal antibodies: their production and characterization. Hybridoma 5: 53

  17. 16.

    Ikebuchi K, Ihle JN, Hirai Y, Wong GG, Clark SC, Wolf SF, Kamen R, Sack L (1988) The myeloid blood cell differentiation-inducing protein MG1–2A is interleukin-6. Blood 72: 2070

  18. 17.

    Jayaraman S, Martin CA, Dorf ME (1990) Enhancement of in vivo cell-mediated immune responses by three distinct cytokines. J Immunol 144: 942

  19. 18.

    Le J, Fredrickson G, Pollack M, Vilcek J (1989) Activation of thymocytes and T cells by interleukin-6. Ann NY Acad Sci 557: 444

  20. 19.

    Lotze M, Jirik F, Kabouridis P, Tsoukas C, Hirano T, Kishimoto T, Carson DA (1988) B cell stimulating factor 2/interleukin-6 is a costimulatant for human thymocytes and T lymphocytes. J Exp Med 167: 1253

  21. 20.

    Lubeck M, Steplewski Z, Baglia F, Klein M, Dorrington K, Koprowski (1985) The interaction of murine IgG subclass proteins with human monocyte Fc receptors. J Immunol 135: 1300

  22. 21.

    Luger TA, Krutmann J, Kirnbauer R, Urbenski A, Schwarz T, Klappacher G, Kock A, Micksche M, Malejczyk J, Schauer E, May G, Sehgal PB (1989) IFN-β2/IL-6 augments the activity of human natural killer cells. J Immunol 143: 1206

  23. 22.

    Malawista SE, Damme JV, Sipe JD, Duff GW, Weiss MC (1989) Independent effects of interleukin-6 (IL-6) and interleukin-1 (IL-1) on accummulation of specific mRNA for fibroinogen and for serum amyloid A in human hepatoma (HepG2) cells. Ann NY Acad Sci 557: 518

  24. 23.

    Masucci G, Wersall P, Ragnhammar P, Mellstedt H (1989) Granulocyte-monocyte colony-stimulating factor augment the cytotoxic capacity of lymphocytes and monocytes in antibody-dependent cellular cytotoxicity. Cancer Immunol Immunother 29: 288

  25. 24.

    Muun DH, Cheung NKV (1987) Interleukin 2 enhancement of monoclonal antibody-mediated cellular cytotoxicity against human melanoma. Cancer Res 47: 6600

  26. 25.

    Muraro R, Nuti M, Natali PG, Bigotti A, Simpson JF, Primus FJ, Colcher D, Greiner JW, Schlom J (1989) A monoclonal antibody (D612) with selective reactivity for malignant and normal gastrointestinal epithelium. Int J Cancer 43: 598

  27. 26.

    Okada M, Kitahara M, Kishimoto S, Matsuda T, Hirano T, Kishimoto T (1988) IL-6/BSF2 functions as a killer helper factor in the in vitro induction of cytotoxic T cells. J Immunol 141: 1543

  28. 27.

    Peoreault J, Bazin R, Lemieux R (1989) Regulation of interleukin-6 dependent B cell hybridoma growth. Ann NY Acad Sci 577: 570

  29. 28.

    Ralph P, Nakorvitz I, Rennick D (1988) Role of interleukin 2, interleukin 4 and α, β, γ interferon in stimulating macrophage antibody dependent tumoricidal activity. J Exp Med 167: 712

  30. 29.

    Sachs L (1987) The molecular control of blood cell development. Science (Washington, DC) 238: 1374

  31. 30.

    Shabo Y, Lotem J, Rubinstein M, Revel M, Clark SC, Wolf SF, Kamen R, Sachs L (1988) The myeloid blood cell differentiation-inducing protein MGI-2A is interleukin-6. Blood 72: 2070

  32. 31.

    Shiloni E, Eisenthal A, Sachs D, Rosenberg SA (1987) Antibody-dependent cellular cytotoxicity mediated by murine lymphocyte activated in recombinant interleukin-2. J Immunol 138: 1992

  33. 32.

    Smith MJ, Ortaldo JR, Bere W, Yagita H, Okumura K, Young HA (1990) IL-2 and IL-6 synergize to augment the pore-forming protein gene expression and cytotoxic potential of human peripheral blood T cells. J Immunol 145: 1159

  34. 33.

    Tosato G, Seamon KB, Goldman ND, Sehgal PB, May LT, Washington GC, Jones K, Pike SE (1988) Identification of a monocytederived human B cell growth factor as interferon-β2 (BSF-2, IL-6). Science 239: 502

  35. 34.

    Tsang KY, Chiofalo MS, La Via MF, Arlen M (1988) Monoclonal antibodies to human colon carcinoma-associated antigens. Fed Proc 6815

  36. 35.

    Van Damme J, Opdenakker G, Simpson RJ, Rubira MR, Cayphas S, Vink A, Billiau A, Van Snick J (1987) Identification of human 26 KD protein, interferon β2 (IFN-β2) as a B cell hybridoma/plasmacytoma factor. J Exp Med 165: 914

  37. 36.

    Van Snick J, Vink A, Cayphas S, Uyttenhove C (1987) Interleukin-HPI, a T cell derived hybridoma growth factor that supports the in vitro growth of murine plasmacytomas. J Exp Med 165: 641

  38. 37.

    Wilson SD, Burd PR, Billings PR, Martin CA, Dorf ME (1988) Expression and regulation of a potential lymphokine gene (TCA3) in CD4 and CD8 T cell clones. J Immunol 141: 1563

Download references

Author information

Correspondence to J. Schlom.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Tsang, K.Y., Finch, M.D., Primus, F.J. et al. Human recombinant interleukin-6 enhances antibody-dependent cellular cytotoxicity of human tumor cells mediated by human peripheral blood mononuclear cells. Cancer Immunol Immunother 34, 9–16 (1991). https://doi.org/10.1007/BF01741318

Download citation

Key words

  • Human rIL-6
  • Antibody-dependent cellular cytotoxicity
  • Peripheral blood
  • Mononuclear cells